The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma.

J Biol Chem · 2025 · PMC12405631 · PMID 40759369

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In PANC1 cells that were not treated with gemcitabine, PLAUR silencing showed a trend toward inhibiting cell migration; however, the results did not achieve statistical significance ( p = 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.